Management of rheumatoid arthritis: Consensus recommendations from the Hong Kong Society of Rheumatology

Clinical Rheumatology

Volumn 30, Issue 3, 2011, Pages 303-312

  Mok, Chi Chiu ^a   Tam, Lai Shan ^b   Chan, Tak Hin ^c   Lee, Gavin K W ^d   Li, Edmund K M ^b  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Private Practice ^*  (Hong Kong)

^d Union Hospital   (Hong Kong)

Author keywords

Hong Kong; Management; Recommendations; Rheumatoid arthritis

Indexed keywords

ABATACEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CHRONIC HEPATITIS; DISABILITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION RISK; JOINT INJURY; MEDICAL SOCIETY; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SCREENING; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS HEPATITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HONG KONG; HUMANS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 79954569790     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1596-y     Document Type: Review

References (76)

1. SE Gabriel K Michaud 2009 Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases Arthritis Res Ther 11 229 19519924 10.1186/ar2669
2. E Lau D Symmons C Bankhead, et al. 1993 Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong J Rheumatol 20 1133 1137 8371205 1:STN:280:DyaK3szotFKiug%3D%3D (Pubitemid 23278163)
3. YJ Xiang SM Dai 2009 Prevalence of rheumatic diseases and disability in China Rheumatol Int 29 481 490 19066899 10.1007/s00296-008-0809-z
4. EH Choy GS Panayi 2001 Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 907 916 11259725 10.1056/ NEJM200103223441207 1:CAS:528:DC%2BD3MXisFyrur8%3D (Pubitemid 32224400)
5. E Olech JE Freeston PG Conaghan, et al. 2008 Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice J Rheumatol 35 580 583 18322995 (Pubitemid 351500052)
6. FC Arnett SM Edworthy DA Bloch, et al. 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 3358796 10.1002/art.1780310302 1:STN:280: DyaL1c7pt1Ohsg%3D%3D (Pubitemid 18091653)
7. D Aletaha T Neogi AJ Silman, et al. 2010 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative Ann Rheum Dis 69 1580 1588 20699241 10.1136/ard.2010.138461
8. CC Mok for the working group on the use of TNF inhibitors for the treatment of rheumatic diseases in Hong Kong 2005 Consensus statements on the indications and monitoring of anti-tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong Hong Kong Bull Rheum Dis 5 19 25
9. B Combe R Landewe C Lukas, et al. 2007 EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 66 34 45 16396980 10.1136/ard.2005.044354 1:STN:280: DC%2BD28jjvFCmsw%3D%3D (Pubitemid 46044858)
10. LR Lard H Visser I Speyer, et al. 2001 Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies Am J Med 111 446 451 11690569 10.1016/S0002-9343(01)00872-5 1:CAS:528:DC%2BD3MXnvFCqsrk%3D (Pubitemid 33016415)
11. JR O'Dell 2004 Therapeutic strategies for Rheumatoid arthritis N Engl J Med 350 2591 2602 15201416 10.1056/NEJMra040226 (Pubitemid 38758546)
12. FC Breedveld MH Weisman AF Kavanaugh, et al. 2006 The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate therapy Arthritis Rheum 54 26 37 16385520 10.1002/art.21519 1:CAS:528:DC%2BD28XhsVens74%3D (Pubitemid 43122183)
13. EW St Clair DM van der Heijde JS Smolen, et al. 2004 Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 3432 3443 15529377 10.1002/art.20568 1:CAS:528:DC%2BD2cXhtVOqtrvJ (Pubitemid 39488667)
14. C Grigor H Capell A Stirling, et al. 2004 Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial Lancet 364 263 269 15262104 10.1016/S0140-6736(04) 16676-2 (Pubitemid 38942816)
15. K Nishimura D Sugiyama Y Kogata, et al. 2007 Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis Ann Intern Med 146 797 808 17548411 (Pubitemid 351650500)
16. RJ Wakefield WW Gibbon PG Conaghan, et al. 2000 The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography Arthritis Rheum 43 2762 2770 11145034 10.1002/1529-0131(200012)43:12<2762::AID-ANR16>3.0.CO;2-# 1:STN:280:DC%2BD3M%2FnvFymug%3D%3D (Pubitemid 32001742)
17. L Poleksic D Zdravkovic D Jablanovic I Watt G Bacic 1993 Magnetic resonance imaging of bone destruction in rheumatoid arthritis: comparison with radiography Skeletal Radiol 22 577 580 8291009 10.1007/BF00197138 1:STN:280:DyaK2c7itVCltg%3D%3D (Pubitemid 23347212)
18. J Fransen PL van Riel 2009 The disease activity score and the EULAR response criteria Rheum Dis Clin North Am 35 745 757 19962619 10.1016/j.rdc.2009.10.001
19. University Medical Centre Nijmegen. DAS-SCORE.NL. Home of the DAS. Available at: http://www.das-score.nl/www.das-score.nl/. Accessed 1 June 2010.
20. KG Saag JR Cerhan S Kolluri K Ohashi GW Hunninghake DA Schwartz 1997 Cigarette smoking and rheumatoid arthritis severity Ann Rheum Dis 56 463 469 9306868 10.1136/ard.56.8.463 1:STN:280:DyaK2svlt1SqtQ%3D%3D (Pubitemid 27396032)
21. B Masdottir T Jónsson V Manfredsdottir A Víkingsson A Brekkan H Valdimarsson 2000 Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis Rheumatology (Oxford) 39 1202 1205 10.1093/rheumatology/39. 11.1202 1:STN:280:DC%2BD3M%2FmtlKjug%3D%3D
22. K Forslind M Ahlmén K Eberhardt I Hafström BARFOT Study Group 2004 Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) Ann Rheum Dis 63 1090 1095 15308518 10.1136/ard.2003.014233 1:CAS:528: DC%2BD2cXnvFWkt7k%3D (Pubitemid 39120360)
23. T Möttönen L Paimela M Leirisalo-Repo H Kautiainen J Ilonen P Hannonen 1998 Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy Ann Rheum Dis 57 533 539 9849312 10.1136/ard.57.9.533 (Pubitemid 28474060)
24. P Richi A Balsa S Muñoz-Fernández, et al. 2002 Factors related to radiological damage in 61 Spaniards with early rheumatoid arthritis Ann Rheum Dis 61 270 272 11830438 10.1136/ard.61.3.270 1:STN:280: DC%2BD38%2FpvFKjsA%3D%3D (Pubitemid 34177763)
25. A Young G Koduri 2007 Extra-articular manifestations and complications of rheumatoid arthritis Best Pract Res Clin Rheumatol 21 907 927 17870035 10.1016/j.berh.2007.05.007 (Pubitemid 47377809)
26. KG Saag GG Teng NM Patkar, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762 784 18512708 10.1002/art.23721 1:CAS:528:DC%2BD1cXot1Wgs74%3D (Pubitemid 351847559)
27. S Lillegraven TK Kvien 2007 Measuring disability and quality of life in established rheumatoid arthritis Best Pract Res Clin Rheumatol 21 827 840 17870030 10.1016/j.berh.2007.05.004 (Pubitemid 47377806)
28. D van der Heijde L Klareskog M Boers, et al. 2005 Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results Ann Rheum Dis 64 1582 1587 15860509 10.1136/ard.2004.034371 (Pubitemid 41532041)
29. ME Weinblatt JS Coblyn DA Fox, et al. 1985 Efficacy of low-dose methotrexate in rheumatoid arthritis N Engl J Med 312 818 822 3883172 10.1056/NEJM198503283121303 1:STN:280:DyaL2M7jslOmtw%3D%3D (Pubitemid 15104774)
30. ME Weinblatt H Kaplan BF Germain, et al. 1994 Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study Arthritis Rheum 37 1492 1498 7945475 10.1002/art.1780371013 1:STN:280:DyaK2M%2Fjt1ahsw%3D%3D (Pubitemid 24337693)
31. T Pincus Y Yazici T Sokka D Aletaha JS Smolen 2003 Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis Clin Exp Rheumatol 21 S179 S185 14969073 1:STN:280:DC%2BD2c%2FotVSjtw%3D%3D
32. TR Mikuls JR O'Dell 2000 The changing face of rheumatoid arthritis therapy: results of serial surveys Arthritis Rheum 43 464 465 10693890 10.1002/1529-0131(200002)43:2<464::AID-ANR30>3.0.CO;2-U 1:STN:280:DC%2BD3c7lsFGmtQ%3D%3D (Pubitemid 30395759)
33. DT Felson JJ Anderson RF Meenan 1990 The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses Arthritis Rheum 33 1449 1461 1977391 10.1002/art.1780331001 1:STN:280:DyaK3M%2FisFWntw%3D%3D (Pubitemid 20362087)
34. M Boers AC Verhoeven HM Markusse, et al. 1997 Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet 350 309 318 9251634 10.1016/S0140-6736(97)01300-7 1:CAS:528:DyaK2sXls1emtbc%3D (Pubitemid 27351112)
35. RB Landewe M Boers AC Verhoeven, et al. 2002 COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention Arthritis Rheum 46 347 356 11840436 10.1002/art.10083 1:CAS:528:DC%2BD38XhvF2ru7s%3D (Pubitemid 34136571)
36. L Klareskog D van der Heijde JP de Jager, et al. 2004 Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675 681 15001324 10.1016/S0140-6736(04)15640-7 1:CAS:528:DC%2BD2cXhs12jur4%3D (Pubitemid 38296553)
37. A Finckh N Bansback CA Marra, et al. 2009 Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis Ann Intern Med 151 668 669
38. JM Kremer MC Genovese GW Cannon, et al. 2002 Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial Ann Intern Med 137 726 733 12416946 1:CAS:528:DC%2BD38XovFylurc%3D (Pubitemid 35265316)
39. US Food and Drug Administration (FDA) Web site. FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm218679.htm. Accessed 31 July 2010.
40. T Möttönen P Hannonen M Leirisalo-Repo, et al. 1999 Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial The Lancet 353 1568 1573 10.1016/S0140-6736(98)08513-4 (Pubitemid 29219206)
41. ME Weinblatt JM Kremer AD Bankhurst, et al. 1999 A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 253 259 9920948 10.1056/NEJM199901283400401 1:CAS:528:DyaK1MXht1Wqsbk%3D (Pubitemid 29063266)
42. EC Keystone AF Kavanaugh JT Sharp, et al. 2004 Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 1400 1411 15146409 10.1002/art.20217 1:CAS:528:DC%2BD2cXkvFykur4%3D (Pubitemid 38608061)
43. RN Maini FC Breedveld JR Kalden, et al. 2004 Sustained improvement over 2 years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 1051 1065 15077287 10.1002/art.20159 1:CAS:528: DC%2BD2cXjslGqsrk%3D (Pubitemid 38480815)
44. P Emery E Keystone HP Tony, et al. 2008 IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologics: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 67 1516 1523 18625622 10.1136/ard.2008.092932 1:CAS:528:DC%2BD1cXhtl2gsbbI
45. RN Maini PC Taylor J Szechinski, et al. 2006 Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 54 2817 2829 16947782 10.1002/art.22033 1:CAS:528:DC%2BD28XhtFWksLjK (Pubitemid 44497760)
46. JS Smolen A Beaulieu A Rubbert-Roth, et al. 2008 Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 987 997 18358926 10.1016/S0140-6736(08)60453-5 1:CAS:528:DC%2BD1cXjs1Sltbc%3D (Pubitemid 351392039)
47. G Jones A Sebba J Gu, et al. 2010 Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 69 88 96 19297346 10.1136/ard.2008.105197 1:CAS:528:DC%2BC3cXhtFOls78%3D
48. Kremer J, Fleischmann R, Halland A, et al. (2008) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study [abstract]. Ann Rheum Dis;58:abstr L14.
49. JM Kremer HK Genant LW Moreland, et al. 2006 Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial Ann Intern Med 144 865 876 16785475 1:CAS:528:DC%2BD28XntF2jsr8%3D (Pubitemid 46768126)
50. JM Kremer HK Genant LW Moreland, et al. 2008 Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate Arthritis Rheum 58 953 963 18383390 10.1002/art.23397 1:CAS:528:DC%2BD1cXltFGisb8%3D (Pubitemid 351563996)
51. SB Cohen P Emery MW Greenwald, et al. 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at 24 weeks Arthritis Rheum 54 2793 2806 16947627 10.1002/art.22025 1:CAS:528:DC%2BD28XhtFWksLjI (Pubitemid 44497758)
52. MC Genovese JC Becker M Schiff, et al. 2005 Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 353 1114 1123 16162882 10.1056/NEJMoa050524 1:CAS:528:DC%2BD2MXhtVWhsbnI (Pubitemid 41317434)
53. JD Isaacs E Olech PP Tak, et al. 2009 Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients Ann Rheum Dis 68 Suppl 3 442
54. J Keane 2005 TNF-blocking agents and tuberculosis: new drugs illuminate an old topic Rheumatology 44 714 720 15741198 10.1093/rheumatology/keh567 1:CAS:528:DC%2BD2MXktl2qt7Y%3D (Pubitemid 41487198)
55. American Thoracic Society Centers for Disease Control and Prevention 2000 This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement Am J Respir Crit Care Med 161 S221 S247
56. LH Calabrese NN Zein D Vassilopoulos 2006 Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 983 989 16627542 10.1136/ard.2005. 043257 1:CAS:528:DC%2BD28XosFahur4%3D (Pubitemid 44133258)
57. DM Nathan PW Angus PR Gibson 2006 Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach J Gastroenterol Hepatol 21 1366 1371 16911678 10.1111/j.1440-1746.2006.04559.x 1:CAS:528:DC%2BD28XhtVOqtLnN (Pubitemid 44154702)
58. Matsue K, Kimura SI, Takanashi Y, et al. (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. [Epub ahead of print]
59. Ji D, Cao J, Hong X, et al. (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. [Epub ahead of print]
60. JH Stone JT Holbrook MA Marriott, et al. 2006 Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial Arthritis Rheum 54 1608 1618 16646004 10.1002/art.21869 1:CAS:528:DC%2BD28XlsFWjsrs%3D
61. J Askling CM Fored L Brandt, et al. 2005 Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Ann Rheum Dis 64 1421 1426 15829572 10.1136/ard.2004.033993 1:STN:280:DC%2BD2MvptFCisw%3D%3D (Pubitemid 41623851)
62. P Geborek A Bladström C Turesson, et al. 2005 Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas Ann Rheum Dis 64 699 703 15695534 10.1136/ard.2004.030528 1:CAS:528:DC%2BD2MXksFWrurc%3D (Pubitemid 40559295)
63. DL Mann JJ McMurray M Packer, et al. 2004 Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 1594 1602 15023878 10.1161/01.CIR.0000124490.27666.B2 1:CAS:528:DC%2BD2cXisFOqtr4%3D (Pubitemid 38451714)
64. ES Chung M Packer KH Lo AA Fasanmade 2003 Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 3133 3140 12796126 10.1161/01.CIR.0000077913.60364.D2 1:CAS:528:DC%2BD3sXkslKgtrs%3D (Pubitemid 36793081)
65. M Ramos-Casals Roberto-Perez-Alvarez C Diaz-Lagares MJ Cuadrado MA Khamashta BIOGEAS Study Group 2010 Autoimmune diseases induced by biologic agents: a double-edged sword? Autoimmun Rev 9 188 193 19854301 10.1016/j.autrev.2009.10.003 1:CAS:528:DC%2BC3cXmtlGnsbc%3D
66. Galloway JB, Hyrich KL, Mercer LK, et al. (2010) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). [Epub ahead of print]
67. J Listing A Strangfeld S Kary, et al. 2005 Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 52 3403 3412 16255017 10.1002/art.21386 1:CAS:528:DC%2BD2MXht1KrtbfF (Pubitemid 41612206)
68. JR Curtis N Patkar A Xie, et al. 2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists Arthritis Rheum 56 1125 1133 17393394 10.1002/art.22504 1:CAS:528:DC%2BD2sXltFKgsrs%3D (Pubitemid 46608637)
69. R Koike M Harigai T Atsumi, et al. 2009 Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis Mod Rheumatol 19 351 357 19590933 10.1007/s10165-009-0197-6 1:CAS:528:DC%2BD1MXptlOgsrc%3D
70. EK Schimmel Y Yazici 2009 Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience Clin Exp Rheumatol 27 446 451 19604437 1:STN:280:DC%2BD1MvoslajsQ%3D%3D
71. C Han DW Robinson MV Hackett, et al. 2006 Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis J Rheumatol 33 2167 2172 16981296 (Pubitemid 44749774)
72. C Turesson A Jarenros L Jacobsson 2004 Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study Ann Rheum Dis 63 952 955 15051620 10.1136/ard.2003.018101 1:STN:280:DC%2BD2czksF2ltw%3D%3D (Pubitemid 38961920)
73. DH Solomon EW Karlson EB RImm, et al. 2003 Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 1303 1307 12628952 10.1161/01.CIR.0000054612.26458.B2 (Pubitemid 36314415)
74. F Wolfe B Freundlich WL Straus 2003 Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis J Rheumatol 30 36 40 12508387 (Pubitemid 36077769)
75. MJ Peters DP Symmons D McCarey, et al. 2010 EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis Ann Rheum Dis 69 325 331 19773290 10.1136/ard.2009.113696 1:STN:280:DC%2BC3c%2Fls12jtg%3D%3D
76. K Deane 2006 Increased prevalence translates into increased fractures-Osteoporosis in RA: a common comorbidity J Musculoskel Med 23 838 844